Global Bio-Artificial Pancreas Market By Clinical Trial (Pre-Clinical, Phase I Clinical Trial, Others); By Condition (Diabetes type 1 (T1D), Diabetes type 2 (T2D); By End-User (Hospitals, Specialty Clinics, Organ Transplant Centers, Research Centers, Others); By Application (Adults, Kids); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 - 2031
Industry Trends
The pancreas happen to be an organ located in the digestive system behind the stomach, in the upper left abdomen. It has two key function, endocrine function and exocrine function. While in the endocrine function, pancreas produce hormones, like insulin and glucagon, which regulate the level of sugar (glucose) in the blood. On the other hand, in the exocrine function, it produces pancreatic juice, which contains enzymes that help break down proteins, fats, and carbohydrates in the small intestine, aiding in digestion. The enzymes produced by the pancreas are released into the small intestine through a duct system. The hormones produced by the pancreas are released directly into the bloodstream and play a critical role in regulating blood sugar levels. Dysfunction or damage to the pancreas can lead to various medical conditions such as diabetes, pancreatitis, or pancreatic cancer. This is where bio-artificial pancreas come into the play. A bio-artificial pancreas, also known as a bio-hybrid pancreas, is a medical device that aims to provide a treatment option for people with type 1 diabetes, who have lost the ability to produce insulin naturally.
The bio-artificial pancreas consists of two main components, which are living cells, and artificial components. Living cells happen to be pancreatic islet cells, which are responsible for producing insulin in the body. The cells are harvested from donors or from the patient's own pancreas, and then cultured and encapsulated in a biocompatible material to protect them from immune attack. Meanwhile, the artificial components are inclusive of a device that allows for the controlled release of insulin and a glucose sensor that can detect changes in blood sugar levels. The bio-artificial pancreas function by implanting the encapsulated cells and artificial components into the patient's body, typically in the abdominal cavity or under the skin. The cells then produce insulin in response to changes in blood sugar levels, which is released through the device and into the bloodstream. The glucose sensor can detect changes in blood sugar levels and adjust insulin release accordingly, providing a more natural and efficient way to regulate blood sugar levels. The demand for bio-artificial pancreas is going up continuously, especially post coronavirus pandemic. The dreadful virus adversely impacted the human immune system, and excessive usage of medicines proved dangerous to the pancreas. On the basis of CAGR, the global bio-artificial pancreas market is anticipated to reach 19.2% over the forecast period (2023 - 2031). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Clinical Trial Outlook
Based on the type outlook, the global bio-artificial pancreas market has been segregated into pre-clinical, phase I clinical trial and others. Despite bio-artificial pancreas technology still being in development and undergoing clinical trials, but it holds promise as a potential treatment option for people with type 1 diabetes who have difficulty controlling their blood sugar levels with traditional insulin therapy. This is the reason why the phase I clinical trials segment accounts for majority of revenue generated by this market.
Region Outlook
On the basis of the region, the continent of North America has been accounting for majority of the money minted by the global bio-artificial pancreas market. Presence of leading medical research companies in the countries like the United States and Canada along with high-tech healthcare infrastructure is driving the market’s growth.
Competitive Landscape
The report provides both, qualitative and quantitative research of global bio-artificial pancreas market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global bio-artificial pancreas market are
- Beta Bionics, Inc.
- Beta-O2 Technologies Ltd
- BIGFOOT BIOMEDICAL, INC.
- Defymed
- Eli Lilly
- Insulet Corporation
- Medtronic
- Tandem
- Other Market Participants
Global Bio-Artificial Pancreas Market:
By Clinical Trial
- Pre-Clinical
- Phase I clinical trial
- Others
By Condition
- Diabetes type 1 (T1D)
- Diabetes type 2 (T2D)
By End-Users
- Hospitals
- Specialty Clinics
- Organ Transplant Centers
- Research Centers
- Others
By Application
- Adults
- Kids
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Forecast Years: 2023 - 2031
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Bio-Artificial Pancreas Market
6. Market Synopsis:
Bio-Artificial Pancreas Market
7. Bio-Artificial Pancreas Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Bio-Artificial Pancreas Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Bio-Artificial
Pancreas Market
7.6. Impact of Covid-19 on Bio-Artificial Pancreas Market
8. Global Bio-Artificial Pancreas Market Analysis and Forecasts,
2023 - 2031
8.1. Overview
8.1.1. Global Bio-Artificial Pancreas Market Revenue (US$ Mn)
8.2. Global Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
8.2.1. Pre-Clinical
8.2.1.1. Definition
8.2.1.2. Market Forecast, 2023 - 2031
8.2.1.3. Compound Annual Growth Rate (CAGR)
8.2.1.4. Regional Bifurcation
8.2.1.4.1. North America
8.2.1.4.1.1. Market
Forecast, 2023 - 2031
8.2.1.4.2. Europe
8.2.1.4.2.1. Market
Forecast, 2023 - 2031
8.2.1.4.3. Asia Pacific
8.2.1.4.3.1. Market
Forecast, 2023 - 2031
8.2.1.4.4. Middle East and Africa
8.2.1.4.4.1. Market
Forecast, 2023 - 2031
8.2.1.4.5. Latin America
8.2.1.4.5.1. Market
Forecast, 2023 - 2031
8.2.2. Phase I clinical trial
8.2.2.1. Definition
8.2.2.2. Market Forecast, 2023 - 2031
8.2.2.3. Compound Annual Growth Rate (CAGR)
8.2.2.4. Regional Bifurcation
8.2.2.4.1. North America
8.2.2.4.1.1. Market
Forecast, 2023 - 2031
8.2.2.4.2. Europe
8.2.2.4.2.1. Market
Forecast, 2023 - 2031
8.2.2.4.3. Asia Pacific
8.2.2.4.3.1. Market
Forecast, 2023 - 2031
8.2.2.4.4. Middle East and Africa
8.2.2.4.4.1. Market
Forecast, 2023 - 2031
8.2.2.4.5. Latin America
8.2.2.4.5.1. Market
Forecast, 2023 - 2031
8.2.3. Others
8.2.3.1. Definition
8.2.3.2. Market Forecast, 2023 - 2031
8.2.3.3. Compound Annual Growth Rate (CAGR)
8.2.3.4. Regional Bifurcation
8.2.3.4.1. North America
8.2.3.4.1.1. Market
Forecast, 2023 - 2031
8.2.3.4.2. Europe
8.2.3.4.2.1. Market
Forecast, 2023 - 2031
8.2.3.4.3. Asia Pacific
8.2.3.4.3.1. Market
Forecast, 2023 - 2031
8.2.3.4.4. Middle East and Africa
8.2.3.4.4.1. Market
Forecast, 2023 - 2031
8.2.3.4.5. Latin America
8.2.3.4.5.1. Market
Forecast, 2023 - 2031
8.3. Key Segment for Channeling Investments
8.3.1. By Clinical Trial
9. Global Bio-Artificial Pancreas Market Analysis and Forecasts,
2023 - 2031
9.1. Overview
9.2. Global Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
9.2.1. Diabetes type 1 (T1D)
9.2.1.1. Definition
9.2.1.2. Market Forecast, 2023 - 2031
9.2.1.3. Compound Annual Growth Rate (CAGR)
9.2.1.4. Regional Bifurcation
9.2.1.4.1. North America
9.2.1.4.1.1. Market
Forecast, 2023 - 2031
9.2.1.4.2. Europe
9.2.1.4.2.1. Market
Forecast, 2023 - 2031
9.2.1.4.3. Asia Pacific
9.2.1.4.3.1. Market
Forecast, 2023 - 2031
9.2.1.4.4. Middle East and Africa
9.2.1.4.4.1. Market
Forecast, 2023 - 2031
9.2.1.4.5. Latin America
9.2.1.4.5.1. Market
Forecast, 2023 - 2031
9.2.2. Diabetes type 2 (T2D)
9.2.2.1. Definition
9.2.2.2. Market Forecast, 2023 - 2031
9.2.2.3. Compound Annual Growth Rate (CAGR)
9.2.2.4. Regional Bifurcation
9.2.2.4.1. North America
9.2.2.4.1.1. Market
Forecast, 2023 - 2031
9.2.2.4.2. Europe
9.2.2.4.2.1. Market
Forecast, 2023 - 2031
9.2.2.4.3. Asia Pacific
9.2.2.4.3.1. Market
Forecast, 2023 - 2031
9.2.2.4.4. Middle East and Africa
9.2.2.4.4.1. Market
Forecast, 2023 - 2031
9.2.2.4.5. Latin America
9.2.2.4.5.1. Market
Forecast, 2023 - 2031
9.3. Key Segment for Channeling Investments
9.3.1. By Condition
10. Global Bio-Artificial Pancreas Market Analysis and Forecasts,
2023 - 2031
10.1. Overview
10.2. Global Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
10.2.1. Hospitals
10.2.1.1. Definition
10.2.1.2. Market Forecast, 2023 - 2031
10.2.1.3. Compound Annual Growth Rate (CAGR)
10.2.1.4. Regional Bifurcation
10.2.1.4.1. North America
10.2.1.4.1.1. Market
Forecast, 2023 - 2031
10.2.1.4.2. Europe
10.2.1.4.2.1. Market
Forecast, 2023 - 2031
10.2.1.4.3. Asia Pacific
10.2.1.4.3.1. Market
Forecast, 2023 - 2031
10.2.1.4.4. Middle East and Africa
10.2.1.4.4.1. Market
Forecast, 2023 - 2031
10.2.1.4.5. Latin America
10.2.1.4.5.1. Market
Forecast, 2023 - 2031
10.2.2. Specialty Clinics
10.2.2.1. Definition
10.2.2.2. Market Forecast, 2023 - 2031
10.2.2.3. Compound Annual Growth Rate (CAGR)
10.2.2.4. Regional Bifurcation
10.2.2.4.1. North America
10.2.2.4.1.1. Market
Forecast, 2023 - 2031
10.2.2.4.2. Europe
10.2.2.4.2.1. Market
Forecast, 2023 - 2031
10.2.2.4.3. Asia Pacific
10.2.2.4.3.1. Market
Forecast, 2023 - 2031
10.2.2.4.4. Middle East and Africa
10.2.2.4.4.1. Market
Forecast, 2023 - 2031
10.2.2.4.5. Latin America
10.2.2.4.5.1. Market
Forecast, 2023 - 2031
10.2.3. Organ Transplant Centers
10.2.3.1. Definition
10.2.3.2. Market Forecast, 2023 - 2031
10.2.3.3. Compound Annual Growth Rate (CAGR)
10.2.3.4. Regional Bifurcation
10.2.3.4.1. North America
10.2.3.4.1.1. Market
Forecast, 2023 - 2031
10.2.3.4.2. Europe
10.2.3.4.2.1. Market
Forecast, 2023 - 2031
10.2.3.4.3. Asia Pacific
10.2.3.4.3.1. Market
Forecast, 2023 - 2031
10.2.3.4.4. Middle East and Africa
10.2.3.4.4.1. Market
Forecast, 2023 - 2031
10.2.3.4.5. Latin America
10.2.3.4.5.1. Market
Forecast, 2023 - 2031
10.2.4. Research Centers
10.2.4.1. Definition
10.2.4.2. Market Forecast, 2023 - 2031
10.2.4.3. Compound Annual Growth Rate (CAGR)
10.2.4.4. Regional Bifurcation
10.2.4.4.1. North America
10.2.4.4.1.1. Market
Forecast, 2023 - 2031
10.2.4.4.2. Europe
10.2.4.4.2.1. Market
Forecast, 2023 - 2031
10.2.4.4.3. Asia Pacific
10.2.4.4.3.1. Market
Forecast, 2023 - 2031
10.2.4.4.4. Middle East and Africa
10.2.4.4.4.1. Market
Forecast, 2023 - 2031
10.2.4.4.5. Latin America
10.2.4.4.5.1. Market
Forecast, 2023 - 2031
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market Forecast, 2023 - 2031
10.2.5.3. Compound Annual Growth Rate (CAGR)
10.2.5.4. Regional Bifurcation
10.2.5.4.1. North America
10.2.5.4.1.1. Market
Forecast, 2023 - 2031
10.2.5.4.2. Europe
10.2.5.4.2.1. Market
Forecast, 2023 - 2031
10.2.5.4.3. Asia Pacific
10.2.5.4.3.1. Market
Forecast, 2023 - 2031
10.2.5.4.4. Middle East and Africa
10.2.5.4.4.1. Market
Forecast, 2023 - 2031
10.2.5.4.5. Latin America
10.2.5.4.5.1. Market
Forecast, 2023 - 2031
10.3. Key Segment for Channeling Investments
10.3.1. By End-Users
11. Global Bio-Artificial Pancreas Market Analysis and Forecasts,
2023 - 2031
11.1. Overview
11.2. Global Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
11.2.1. Adults
11.2.1.1. Definition
11.2.1.2. Market Forecast, 2023 - 2031
11.2.1.3. Compound Annual Growth Rate (CAGR)
11.2.1.4. Regional Bifurcation
11.2.1.4.1. North America
11.2.1.4.1.1. Market
Forecast, 2023 - 2031
11.2.1.4.2. Europe
11.2.1.4.2.1. Market
Forecast, 2023 - 2031
11.2.1.4.3. Asia Pacific
11.2.1.4.3.1. Market
Forecast, 2023 - 2031
11.2.1.4.4. Middle East and Africa
11.2.1.4.4.1. Market
Forecast, 2023 - 2031
11.2.1.4.5. Latin America
11.2.1.4.5.1. Market
Forecast, 2023 - 2031
11.2.2. Kids
11.2.2.1. Definition
11.2.2.2. Market Forecast, 2023 - 2031
11.2.2.3. Compound Annual Growth Rate (CAGR)
11.2.2.4. Regional Bifurcation
11.2.2.4.1. North America
11.2.2.4.1.1. Market
Forecast, 2023 - 2031
11.2.2.4.2. Europe
11.2.2.4.2.1. Market
Forecast, 2023 - 2031
11.2.2.4.3. Asia Pacific
11.2.2.4.3.1. Market
Forecast, 2023 - 2031
11.2.2.4.4. Middle East and Africa
11.2.2.4.4.1. Market
Forecast, 2023 - 2031
11.2.2.4.5. Latin America
11.2.2.4.5.1. Market
Forecast, 2023 - 2031
11.3. Key Segment for Channeling Investments
11.3.1. By Application
12. North America Bio-Artificial Pancreas Market Analysis and
Forecasts, 2023 - 2031
12.1. Overview
12.1.1. North America Bio-Artificial Pancreas Market Revenue (US$ Mn)
12.2. North America Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial
12.2.1. Pre-Clinical
12.2.2. Phase I clinical trial
12.2.3. Others
12.3. North America Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Condition
12.3.1. Diabetes type 1 (T1D)
12.3.2. Diabetes type 2 (T2D)
12.4. North America Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By End-Users
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Organ Transplant Centers
12.4.4. Research Centers
12.4.5. Others
12.5. North America Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Application
12.5.1. Adults
12.5.2. Kids
12.6. North America Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
12.6.1.1.1. Pre-Clinical
12.6.1.1.2. Phase I clinical trial
12.6.1.1.3. Others
12.6.1.2. U.S Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
12.6.1.2.1. Diabetes type 1 (T1D)
12.6.1.2.2. Diabetes type 2 (T2D)
12.6.1.3. U.S Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
12.6.1.3.1. Hospitals
12.6.1.3.2. Specialty Clinics
12.6.1.3.3. Organ Transplant Centers
12.6.1.3.4. Research Centers
12.6.1.3.5. Others
12.6.1.4. U.S Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.1.4.1. Adults
12.6.1.4.2. Kids
12.6.2. Canada
12.6.2.1. Canada Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
12.6.2.1.1. Pre-Clinical
12.6.2.1.2. Phase I clinical trial
12.6.2.1.3. Others
12.6.2.2. Canada Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
12.6.2.2.1. Diabetes type 1 (T1D)
12.6.2.2.2. Diabetes type 2 (T2D)
12.6.2.3. Canada Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
12.6.2.3.1. Hospitals
12.6.2.3.2. Specialty Clinics
12.6.2.3.3. Organ Transplant Centers
12.6.2.3.4. Research Centers
12.6.2.3.5. Others
12.6.2.4. Canada Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.2.4.1. Adults
12.6.2.4.2. Kids
12.6.3. Mexico
12.6.3.1. Mexico Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
12.6.3.1.1. Pre-Clinical
12.6.3.1.2. Phase I clinical trial
12.6.3.1.3. Others
12.6.3.2. Mexico Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
12.6.3.2.1. Diabetes type 1 (T1D)
12.6.3.2.2. Diabetes type 2 (T2D)
12.6.3.3. Mexico Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
12.6.3.3.1. Hospitals
12.6.3.3.2. Specialty Clinics
12.6.3.3.3. Organ Transplant Centers
12.6.3.3.4. Research Centers
12.6.3.3.5. Others
12.6.3.4. Mexico Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.3.4.1. Adults
12.6.3.4.2. Kids
12.6.4. Rest of North America
12.6.4.1. Rest of North America Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial
12.6.4.1.1. Pre-Clinical
12.6.4.1.2. Phase I clinical trial
12.6.4.1.3. Others
12.6.4.2. Rest of North America Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Condition
12.6.4.2.1. Diabetes type 1 (T1D)
12.6.4.2.2. Diabetes type 2 (T2D)
12.6.4.3. Rest of North America Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By End-Users
12.6.4.3.1. Hospitals
12.6.4.3.2. Specialty Clinics
12.6.4.3.3. Organ Transplant Centers
12.6.4.3.4. Research Centers
12.6.4.3.5. Others
12.6.4.4. Rest of North America Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Application
12.6.4.4.1. Adults
12.6.4.4.2. Kids
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Clinical Trial
12.7.3. By Condition
12.7.4. By End-Users
12.7.5. By Application
13. Europe Bio-Artificial Pancreas Market Analysis and Forecasts,
2023 - 2031
13.1. Overview
13.1.1. Europe Bio-Artificial Pancreas Market Revenue (US$ Mn)
13.2. Europe Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
13.2.1. Pre-Clinical
13.2.2. Phase I clinical trial
13.2.3. Others
13.3. Europe Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
13.3.1. Diabetes type 1 (T1D)
13.3.2. Diabetes type 2 (T2D)
13.4. Europe Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Organ Transplant Centers
13.4.4. Research Centers
13.4.5. Others
13.5. Europe Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.1. Adults
13.5.2. Kids
13.6. Europe Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.1. France
13.6.1.1. France Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
13.6.1.1.1. Pre-Clinical
13.6.1.1.2. Phase I clinical trial
13.6.1.1.3. Others
13.6.1.2. France Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
13.6.1.2.1. Diabetes type 1 (T1D)
13.6.1.2.2. Diabetes type 2 (T2D)
13.6.1.3. France Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
13.6.1.3.1. Hospitals
13.6.1.3.2. Specialty Clinics
13.6.1.3.3. Organ Transplant Centers
13.6.1.3.4. Research Centers
13.6.1.3.5. Others
13.6.1.4. France Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.1.4.1. Adults
13.6.1.4.2. Kids
13.6.2. The UK
13.6.2.1. The UK Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
13.6.2.1.1. Pre-Clinical
13.6.2.1.2. Phase I clinical trial
13.6.2.1.3. Others
13.6.2.2. The UK Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
13.6.2.2.1. Diabetes type 1 (T1D)
13.6.2.2.2. Diabetes type 2 (T2D)
13.6.2.3. The UK Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
13.6.2.3.1. Hospitals
13.6.2.3.2. Specialty Clinics
13.6.2.3.3. Organ Transplant Centers
13.6.2.3.4. Research Centers
13.6.2.3.5. Others
13.6.2.4. The UK Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.2.4.1. Adults
13.6.2.4.2. Kids
13.6.3. Spain
13.6.3.1. Spain Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
13.6.3.1.1. Pre-Clinical
13.6.3.1.2. Phase I clinical trial
13.6.3.1.3. Others
13.6.3.2. Spain Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
13.6.3.2.1. Diabetes type 1 (T1D)
13.6.3.2.2. Diabetes type 2 (T2D)
13.6.3.3. Spain Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
13.6.3.3.1. Hospitals
13.6.3.3.2. Specialty Clinics
13.6.3.3.3. Organ Transplant Centers
13.6.3.3.4. Research Centers
13.6.3.3.5. Others
13.6.3.4. Spain Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.3.4.1. Adults
13.6.3.4.2. Kids
13.6.4. Germany
13.6.4.1. Germany Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
13.6.4.1.1. Pre-Clinical
13.6.4.1.2. Phase I clinical trial
13.6.4.1.3. Others
13.6.4.2. Germany Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
13.6.4.2.1. Diabetes type 1 (T1D)
13.6.4.2.2. Diabetes type 2 (T2D)
13.6.4.3. Germany Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
13.6.4.3.1. Hospitals
13.6.4.3.2. Specialty Clinics
13.6.4.3.3. Organ Transplant Centers
13.6.4.3.4. Research Centers
13.6.4.3.5. Others
13.6.4.4. Germany Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.4.4.1. Adults
13.6.4.4.2. Kids
13.6.5. Italy
13.6.5.1. Italy Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
13.6.5.1.1. Pre-Clinical
13.6.5.1.2. Phase I clinical trial
13.6.5.1.3. Others
13.6.5.2. Italy Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
13.6.5.2.1. Diabetes type 1 (T1D)
13.6.5.2.2. Diabetes type 2 (T2D)
13.6.5.3. Italy Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
13.6.5.3.1. Hospitals
13.6.5.3.2. Specialty Clinics
13.6.5.3.3. Organ Transplant Centers
13.6.5.3.4. Research Centers
13.6.5.3.5. Others
13.6.5.4. Italy Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.5.4.1. Adults
13.6.5.4.2. Kids
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Bio-Artificial Pancreas Market Revenue (US$
Mn) and Forecasts, By Clinical Trial
13.6.6.1.1. Pre-Clinical
13.6.6.1.2. Phase I clinical trial
13.6.6.1.3. Others
13.6.6.2. Nordic Countries Bio-Artificial Pancreas Market Revenue (US$
Mn) and Forecasts, By Condition
13.6.6.2.1. Diabetes type 1 (T1D)
13.6.6.2.2. Diabetes type 2 (T2D)
13.6.6.3. Nordic Countries Bio-Artificial Pancreas Market Revenue (US$
Mn) and Forecasts, By End-Users
13.6.6.3.1. Hospitals
13.6.6.3.2. Specialty Clinics
13.6.6.3.3. Organ Transplant Centers
13.6.6.3.4. Research Centers
13.6.6.3.5. Others
13.6.6.4. Nordic Countries Bio-Artificial Pancreas Market Revenue (US$
Mn) and Forecasts, By Application
13.6.6.4.1. Adults
13.6.6.4.2. Kids
13.6.6.5. Nordic Countries Bio-Artificial Pancreas Market Revenue (US$
Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux Union
13.6.7.1. Benelux Union Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial
13.6.7.1.1. Pre-Clinical
13.6.7.1.2. Phase I clinical trial
13.6.7.1.3. Others
13.6.7.2. Benelux Union Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Condition
13.6.7.2.1. Diabetes type 1 (T1D)
13.6.7.2.2. Diabetes type 2 (T2D)
13.6.7.3. Benelux Union Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By End-Users
13.6.7.3.1. Hospitals
13.6.7.3.2. Specialty Clinics
13.6.7.3.3. Organ Transplant Centers
13.6.7.3.4. Research Centers
13.6.7.3.5. Others
13.6.7.4. Benelux Union Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.7.4.1. Adults
13.6.7.4.2. Kids
13.6.7.5. Benelux Union Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial
13.6.8.1.1. Pre-Clinical
13.6.8.1.2. Phase I clinical trial
13.6.8.1.3. Others
13.6.8.2. Rest of Europe Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Condition
13.6.8.2.1. Diabetes type 1 (T1D)
13.6.8.2.2. Diabetes type 2 (T2D)
13.6.8.3. Rest of Europe Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By End-Users
13.6.8.3.1. Hospitals
13.6.8.3.2. Specialty Clinics
13.6.8.3.3. Organ Transplant Centers
13.6.8.3.4. Research Centers
13.6.8.3.5. Others
13.6.8.4. Rest of Europe Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.8.4.1. Adults
13.6.8.4.2. Kids
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Clinical Trial
13.7.3. By Condition
13.7.4. By End-Users
13.7.5. By Application
14. Asia Pacific Bio-Artificial Pancreas Market Analysis and
Forecasts, 2023 - 2031
14.1. Overview
14.1.1. Asia Pacific Bio-Artificial Pancreas Market Revenue (US$ Mn)
14.2. Asia Pacific Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial
14.2.1. Pre-Clinical
14.2.2. Phase I clinical trial
14.2.3. Others
14.3. Asia Pacific Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Condition
14.3.1. Diabetes type 1 (T1D)
14.3.2. Diabetes type 2 (T2D)
14.4. Asia Pacific Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By End-Users
14.4.1. Hospitals
14.4.2. Specialty Clinics
14.4.3. Organ Transplant Centers
14.4.4. Research Centers
14.4.5. Others
14.5. Asia Pacific Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Application
14.5.1. Adults
14.5.2. Kids
14.6. Asia Pacific Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Country
14.6.1. China
14.6.1.1. China Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
14.6.1.1.1. Pre-Clinical
14.6.1.1.2. Phase I clinical trial
14.6.1.1.3. Others
14.6.1.2. China Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
14.6.1.2.1. Diabetes type 1 (T1D)
14.6.1.2.2. Diabetes type 2 (T2D)
14.6.1.3. China Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
14.6.1.3.1. Hospitals
14.6.1.3.2. Specialty Clinics
14.6.1.3.3. Organ Transplant Centers
14.6.1.3.4. Research Centers
14.6.1.3.5. Others
14.6.1.4. China Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.1.4.1. Adults
14.6.1.4.2. Kids
14.6.2. Japan
14.6.2.1. Japan Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
14.6.2.1.1. Pre-Clinical
14.6.2.1.2. Phase I clinical trial
14.6.2.1.3. Others
14.6.2.2. Japan Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
14.6.2.2.1. Diabetes type 1 (T1D)
14.6.2.2.2. Diabetes type 2 (T2D)
14.6.2.3. Japan Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
14.6.2.3.1. Hospitals
14.6.2.3.2. Specialty Clinics
14.6.2.3.3. Organ Transplant Centers
14.6.2.3.4. Research Centers
14.6.2.3.5. Others
14.6.2.4. Japan Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.2.4.1. Adults
14.6.2.4.2. Kids
14.6.3. India
14.6.3.1. India Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
14.6.3.1.1. Pre-Clinical
14.6.3.1.2. Phase I clinical trial
14.6.3.1.3. Others
14.6.3.2. India Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
14.6.3.2.1. Diabetes type 1 (T1D)
14.6.3.2.2. Diabetes type 2 (T2D)
14.6.3.3. India Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
14.6.3.3.1. Hospitals
14.6.3.3.2. Specialty Clinics
14.6.3.3.3. Organ Transplant Centers
14.6.3.3.4. Research Centers
14.6.3.3.5. Others
14.6.3.4. India Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.3.4.1. Adults
14.6.3.4.2. Kids
14.6.4. New Zealand
14.6.4.1. New Zealand Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial
14.6.4.1.1. Pre-Clinical
14.6.4.1.2. Phase I clinical trial
14.6.4.1.3. Others
14.6.4.2. New Zealand Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Condition
14.6.4.2.1. Diabetes type 1 (T1D)
14.6.4.2.2. Diabetes type 2 (T2D)
14.6.4.3. New Zealand Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By End-Users
14.6.4.3.1. Hospitals
14.6.4.3.2. Specialty Clinics
14.6.4.3.3. Organ Transplant Centers
14.6.4.3.4. Research Centers
14.6.4.3.5. Others
14.6.4.4. New Zealand Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.4.4.1. Adults
14.6.4.4.2. Kids
14.6.5. Australia
14.6.5.1. Australia Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
14.6.5.1.1. Pre-Clinical
14.6.5.1.2. Phase I clinical trial
14.6.5.1.3. Others
14.6.5.2. Australia Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
14.6.5.2.1. Diabetes type 1 (T1D)
14.6.5.2.2. Diabetes type 2 (T2D)
14.6.5.3. Australia Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
14.6.5.3.1. Hospitals
14.6.5.3.2. Specialty Clinics
14.6.5.3.3. Organ Transplant Centers
14.6.5.3.4. Research Centers
14.6.5.3.5. Others
14.6.5.4. Australia Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.5.4.1. Adults
14.6.5.4.2. Kids
14.6.6. South Korea
14.6.6.1. South Korea Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial
14.6.6.1.1. Pre-Clinical
14.6.6.1.2. Phase I clinical trial
14.6.6.1.3. Others
14.6.6.2. South Korea Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Condition
14.6.6.2.1. Diabetes type 1 (T1D)
14.6.6.2.2. Diabetes type 2 (T2D)
14.6.6.3. South Korea Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By End-Users
14.6.6.3.1. Hospitals
14.6.6.3.2. Specialty Clinics
14.6.6.3.3. Organ Transplant Centers
14.6.6.3.4. Research Centers
14.6.6.3.5. Others
14.6.6.4. South Korea Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.6.4.1. Adults
14.6.6.4.2. Kids
14.6.7. Southeast Asia
14.6.7.1. Southeast Asia Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial
14.6.7.1.1. Pre-Clinical
14.6.7.1.2. Phase I clinical trial
14.6.7.1.3. Others
14.6.7.2. Southeast Asia Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Condition
14.6.7.2.1. Diabetes type 1 (T1D)
14.6.7.2.2. Diabetes type 2 (T2D)
14.6.7.3. Southeast Asia Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By End-Users
14.6.7.3.1. Hospitals
14.6.7.3.2. Specialty Clinics
14.6.7.3.3. Organ Transplant Centers
14.6.7.3.4. Research Centers
14.6.7.3.5. Others
14.6.7.4. Southeast Asia Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.7.4.1. Adults
14.6.7.4.2. Kids
14.6.7.5. Southeast Asia Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial
14.6.8.1.1. Pre-Clinical
14.6.8.1.2. Phase I clinical trial
14.6.8.1.3. Others
14.6.8.2. Rest of Asia Pacific Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Condition
14.6.8.2.1. Diabetes type 1 (T1D)
14.6.8.2.2. Diabetes type 2 (T2D)
14.6.8.3. Rest of Asia Pacific Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By End-Users
14.6.8.3.1. Hospitals
14.6.8.3.2. Specialty Clinics
14.6.8.3.3. Organ Transplant Centers
14.6.8.3.4. Research Centers
14.6.8.3.5. Others
14.6.8.4. Rest of Asia Pacific Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.8.4.1. Adults
14.6.8.4.2. Kids
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Clinical Trial
14.7.3. By Condition
14.7.4. By End-Users
14.7.5. By Application
15. Middle East and Africa Bio-Artificial Pancreas Market
Analysis and Forecasts, 2023 - 2031
15.1. Overview
15.1.1. Middle East and Africa Bio-Artificial Pancreas Market Revenue
(US$ Mn)
15.2. Middle East and Africa Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial
15.2.1. Pre-Clinical
15.2.2. Phase I clinical trial
15.2.3. Others
15.3. Middle East and Africa Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Condition
15.3.1. Diabetes type 1 (T1D)
15.3.2. Diabetes type 2 (T2D)
15.4. Middle East and Africa Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By End-Users
15.4.1. Hospitals
15.4.2. Specialty Clinics
15.4.3. Organ Transplant Centers
15.4.4. Research Centers
15.4.5. Others
15.5. Middle East and Africa Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Application
15.5.1. Adults
15.5.2. Kids
15.6. Middle East and Africa Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1. Saudi Arabia Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial
15.6.1.1.1. Pre-Clinical
15.6.1.1.2. Phase I clinical trial
15.6.1.1.3. Others
15.6.1.2. Saudi Arabia Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Condition
15.6.1.2.1. Diabetes type 1 (T1D)
15.6.1.2.2. Diabetes type 2 (T2D)
15.6.1.3. Saudi Arabia Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By End-Users
15.6.1.3.1. Hospitals
15.6.1.3.2. Specialty Clinics
15.6.1.3.3. Organ Transplant Centers
15.6.1.3.4. Research Centers
15.6.1.3.5. Others
15.6.1.4. Saudi Arabia Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.1.4.1. Adults
15.6.1.4.2. Kids
15.6.2. UAE
15.6.2.1. UAE Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
15.6.2.1.1. Pre-Clinical
15.6.2.1.2. Phase I clinical trial
15.6.2.1.3. Others
15.6.2.2. UAE Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
15.6.2.2.1. Diabetes type 1 (T1D)
15.6.2.2.2. Diabetes type 2 (T2D)
15.6.2.3. UAE Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
15.6.2.3.1. Hospitals
15.6.2.3.2. Specialty Clinics
15.6.2.3.3. Organ Transplant Centers
15.6.2.3.4. Research Centers
15.6.2.3.5. Others
15.6.2.4. UAE Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.2.4.1. Adults
15.6.2.4.2. Kids
15.6.3. Egypt
15.6.3.1. Egypt Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
15.6.3.1.1. Pre-Clinical
15.6.3.1.2. Phase I clinical trial
15.6.3.1.3. Others
15.6.3.2. Egypt Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
15.6.3.2.1. Diabetes type 1 (T1D)
15.6.3.2.2. Diabetes type 2 (T2D)
15.6.3.3. Egypt Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
15.6.3.3.1. Hospitals
15.6.3.3.2. Specialty Clinics
15.6.3.3.3. Organ Transplant Centers
15.6.3.3.4. Research Centers
15.6.3.3.5. Others
15.6.3.4. Egypt Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.3.4.1. Adults
15.6.3.4.2. Kids
15.6.4. Kuwait
15.6.4.1. Kuwait Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
15.6.4.1.1. Pre-Clinical
15.6.4.1.2. Phase I clinical trial
15.6.4.1.3. Others
15.6.4.2. Kuwait Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
15.6.4.2.1. Diabetes type 1 (T1D)
15.6.4.2.2. Diabetes type 2 (T2D)
15.6.4.3. Kuwait Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
15.6.4.3.1. Hospitals
15.6.4.3.2. Specialty Clinics
15.6.4.3.3. Organ Transplant Centers
15.6.4.3.4. Research Centers
15.6.4.3.5. Others
15.6.4.4. Kuwait Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.4.4.1. Adults
15.6.4.4.2. Kids
15.6.5. South Africa
15.6.5.1. South Africa Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial
15.6.5.1.1. Pre-Clinical
15.6.5.1.2. Phase I clinical trial
15.6.5.1.3. Others
15.6.5.2. South Africa Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Condition
15.6.5.2.1. Diabetes type 1 (T1D)
15.6.5.2.2. Diabetes type 2 (T2D)
15.6.5.3. South Africa Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By End-Users
15.6.5.3.1. Hospitals
15.6.5.3.2. Specialty Clinics
15.6.5.3.3. Organ Transplant Centers
15.6.5.3.4. Research Centers
15.6.5.3.5. Others
15.6.5.4. South Africa Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.5.4.1. Adults
15.6.5.4.2. Kids
15.6.6. Rest of Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Bio-Artificial Pancreas
Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
15.6.6.1.1. Pre-Clinical
15.6.6.1.2. Phase I clinical trial
15.6.6.1.3. Others
15.6.6.2. Rest of Middle East & Africa Bio-Artificial Pancreas
Market Revenue (US$ Mn) and Forecasts, By Condition
15.6.6.2.1. Diabetes type 1 (T1D)
15.6.6.2.2. Diabetes type 2 (T2D)
15.6.6.3. Rest of Middle East & Africa Bio-Artificial Pancreas
Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.6.3.1. Hospitals
15.6.6.3.2. Specialty Clinics
15.6.6.3.3. Organ Transplant Centers
15.6.6.3.4. Research Centers
15.6.6.3.5. Others
15.6.6.4. Rest of Middle East & Africa Bio-Artificial Pancreas
Market Revenue (US$ Mn) and Forecasts, By Application
15.6.6.4.1. Adults
15.6.6.4.2. Kids
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Clinical Trial
15.7.3. By Condition
15.7.4. By End-Users
15.7.5. By Application
16. Latin America Bio-Artificial Pancreas Market Analysis and
Forecasts, 2023 - 2031
16.1. Overview
16.1.1. Latin America Bio-Artificial Pancreas Market Revenue (US$ Mn)
16.2. Latin America Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial
16.2.1. Pre-Clinical
16.2.2. Phase I clinical trial
16.2.3. Others
16.3. Latin America Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Condition
16.3.1. Diabetes type 1 (T1D)
16.3.2. Diabetes type 2 (T2D)
16.4. Latin America Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By End-Users
16.4.1. Hospitals
16.4.2. Specialty Clinics
16.4.3. Organ Transplant Centers
16.4.4. Research Centers
16.4.5. Others
16.5. Latin America Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Application
16.5.1. Adults
16.5.2. Kids
16.6. Latin America Bio-Artificial Pancreas Market Revenue (US$ Mn)
and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
16.6.1.1.1. Pre-Clinical
16.6.1.1.2. Phase I clinical trial
16.6.1.1.3. Others
16.6.1.2. Brazil Bio-Artificial Pancreas Market Revenue (US$ Mn) and Forecasts,
By Condition
16.6.1.2.1. Diabetes type 1 (T1D)
16.6.1.2.2. Diabetes type 2 (T2D)
16.6.1.3. Brazil Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
16.6.1.3.1. Hospitals
16.6.1.3.2. Specialty Clinics
16.6.1.3.3. Organ Transplant Centers
16.6.1.3.4. Research Centers
16.6.1.3.5. Others
16.6.1.4. Brazil Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
16.6.1.4.1. Adults
16.6.1.4.2. Kids
16.6.2. Argentina
16.6.2.1. Argentina Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
16.6.2.1.1. Pre-Clinical
16.6.2.1.2. Phase I clinical trial
16.6.2.1.3. Others
16.6.2.2. Argentina Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Condition
16.6.2.2.1. Diabetes type 1 (T1D)
16.6.2.2.2. Diabetes type 2 (T2D)
16.6.2.3. Argentina Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By End-Users
16.6.2.3.1. Hospitals
16.6.2.3.2. Specialty Clinics
16.6.2.3.3. Organ Transplant Centers
16.6.2.3.4. Research Centers
16.6.2.3.5. Others
16.6.2.4. Argentina Bio-Artificial Pancreas Market Revenue (US$ Mn) and
Forecasts, By Application
16.6.2.4.1. Adults
16.6.2.4.2. Kids
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial
16.6.3.1.1. Pre-Clinical
16.6.3.1.2. Phase I clinical trial
16.6.3.1.3. Others
16.6.3.2. Rest of Latin America Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Condition
16.6.3.2.1. Diabetes type 1 (T1D)
16.6.3.2.2. Diabetes type 2 (T2D)
16.6.3.3. Rest of Latin America Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By End-Users
16.6.3.3.1. Hospitals
16.6.3.3.2. Specialty Clinics
16.6.3.3.3. Organ Transplant Centers
16.6.3.3.4. Research Centers
16.6.3.3.5. Others
16.6.3.4. Rest of Latin America Bio-Artificial Pancreas Market Revenue
(US$ Mn) and Forecasts, By Application
16.6.3.4.1. Adults
16.6.3.4.2. Kids
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Clinical Trial
16.7.3. By Condition
16.7.4. By End-Users
16.7.5. By Application
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. Beta Bionics, Inc.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Beta-O2 Technologies Ltd
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. BIGFOOT BIOMEDICAL, INC.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Defymed
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Eli Lilly
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Insulet Corporation
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Medtronic
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Tandem
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.